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Biosynthesis of the antibiotic nonribosomal peptide
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Fungi are a valuable source of enzymatic diversity and therapeutic natural products including
antibiotics. Here we engineer the baker’s yeast Saccharomyces cerevisiae to produce and
secrete the antibiotic penicillin, a beta-lactam nonribosomal peptide, by taking genes from a
filamentous fungus and directing their efficient expression and subcellular localization. Using
synthetic biology tools combined with long-read DNA sequencing, we optimize productivity
by 50-fold to produce bioactive yields that allow spent S. cerevisiae growth media to have
antibacterial action against Streptococcus bacteria. This work demonstrates that S. cerevisiae
can be engineered to perform the complex biosynthesis of multicellular fungi, opening up the
possibility of using yeast to accelerate rational engineering of nonribosomal peptide
antibiotics.
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M
any important therapeutics including key antibiotics
are derived from compounds produced by fungal
organisms1, yet fungal enzymatic diversity is a largely
untapped resource for cheap biosynthesis of medical molecules
and the potential for the discovery of novel therapeutics2,3.
The baker’s yeast Saccharomyces cerevisiae is the most
well-characterized unicellular fungus and is also one of the
main organisms used industrially for engineered biosynthesis4.
Since the advent of synthetic biology, S. cerevisiae has been
genetically reprogrammed to express diverse enzymes from
bacteria and eukaryotes, producing hundreds of different
molecules of industrial and therapeutic relevance including
opiates and anti-malarial terpenoids5–9. A major class of
bioactive molecules found in fungi as well as in bacteria are the
non-ribosomal peptides (Nrp), a diverse set of complex molecules
produced by large assembly-line enzymes called non-ribosomal
peptide synthetases (NRPS). Non-ribosomal peptides include
many front-line antibiotics including the classic beta-lactam
antibiotic penicillin, which is naturally made by filamentous
fungi10,11.
To provide the foundations for using synthetic biology to
produce fungal-derived Nrp molecules in a tractable host, we set
out here to demonstrate that cells can be engineered to make the
benchmark therapeutic penicillin. Despite a wide range of known
fungal NRPS genes and the plethora of advanced genetic tools for
S. cerevisiae, there have been no reports of engineered beta-lactam
antibiotic production from this yeast. As is the case for most
bioactive Nrp molecules, the biosynthesis of penicillin requires
not only expression of the NRPS but also the coordinated
expression of a pathway of tailoring enzymes that convert the
Nrp into its active form. Previously, Siewers et al.12 showed that
co-expression of the Penicillium chrysogenum NRPS gene pcbAB
and an NPRS activator gene in S. cerevisiae led to cytosolic
synthesis of amino-adipyl-cysteinyl-valine (ACV), the Nrp
intermediate in the five gene P. chrysogenum pathway of
penicillin G (benzylpenicillin) biosynthesis. While this revealed
that the first step of beta-lactam production was possible in
S. cerevisiae, the pathway to producing an active Nrp antibiotic
was incomplete. Using modular genetic tools to control enzyme
expression, we demonstrate here that correct subcellular
localization, along with expression optimization of the full five
gene fungal pathway enables S. cerevisiae to synthesize
benzylpenicillin. We further demonstrate that bioactive
benzylpenicillin is secreted by our engineered yeast and that
spent culture media has antibiotic activity against Streptococcus
bacteria enabling a simple biological assay for productive strains.
Results
Establishing benzylpenicillin biosynthesis in S. cerevisiae. The
benzylpenicillin pathway in P. chrysogenum consists of five genes
converting cysteine, valine and the non-canonical amino acid
alpha-aminoadipic acid into a beta-lactam antibiotic via ACV
(Fig. 1a). The 11.3 kbp NRPS gene pcbAB and the NRPS activator
gene npgA required to produce ACV were first integrated into the
S. cerevisiae BY4741 TRP1 locus by inserting the two genes and
the bidirectional GAL1/GAL10 promoters from the previously
described pESC-npgA-pcbAB plasmid12. ACV production in this
strain (Sc.A1) was then confirmed using liquid chromatography
mass spectrometry (LCMS) comparing to a chemical standard
(Fig. 1b). To complete the pathway and establish benzylpenicillin
biosynthesis in S. cerevisiae, we next required efficient expression
of the remaining three P. chrysogenum enzymes. However, as the
final two steps of this pathway are known to naturally occur
in the peroxisome in P. chrysogenum13, we reasoned that
cytoplasmic expression of all enzymes would not suffice and
that subcellular localization would be the key to full synthesis.
We therefore took the step of tagging both pclA and penDE with
the previously characterized S. cerevisiae peroxisome targeting
sequence (PTS1) tag14 and removing the native P. chrysogenum
PTS1 tags to direct these enzymes to co-localize in the
peroxisome on translation. To verify expression and correct
subcellular localization of these two enzymes, we used
fluorescence tagging and microscopy to show that a known
S. cerevisiae peroxisomal protein (CIT2) co-localizes with both
pclA and penDE tagged with S. cerevisiae PTS1 (Supplementary
Fig. 1). Furthermore, variants of pclA and penDE harbouring the
native P. chrysogenum peroxisome targeting tag did not localize to
S. cerevisiae peroxisomes and peroxisomal localization for
CIT2, pclA and penDE was abolished in a strain in which
the PTS1-recognizing peroxisome importer pex5 was deleted
(Supplementary Fig. 1).
To test whether simultaneous expression of all five genes could
result in benzylpenicillin production, we transformed a plasmid
harbouring pcbC and the S. cerevisiae PTS1-tagged pclA and
penDE into the Sc.A1 strain. The resulting strain (Sc.P1) was
shown to indeed produce very low quantities of benzylpenicillin
when measured by LCMS (Fig. 1c). By contrast, a strain
harbouring pclA and penDE with P. chrysogenum peroxisome
targeting sequences (Sc.P1x) produced ACV but failed to produce
any benzylpenicillin (Fig. 1c). Finally, while the ACV Nrp
intermediate was detected at equal amounts inside and outside
cells, benzylpenicillin was found predominantly in supernatant
fractions (at B90 pgml 1), suggesting active secretion of the
antibiotic (Fig. 1d).
Combinatorial pathway optimization and nanopore sequencing.
Considering the small amounts of benzylpenicillin produced by
the first engineered strain Sc.P1, we next sought to optimize
production of benzylpenicillin in S. cerevisiae to achieve bioactive
concentrations. One common strategy for improving biosynthesis
yields is to alter the expression levels of the pathway enzymes,
typically by changing the promoters for the corresponding
genes15. This can increase the flux through the pathway
preventing the build-up of any inhibitory intermediates16 and
can also aid in finding efficient expression levels of enzymes
that allow their correct folding and subcellular localization,
both important considerations for this case. Using a recently
described modular cloning toolkit for yeast17 and Golden Gate
combinatorial DNA assembly18 we constructed and tested
hundreds of different combinations of the benzylpenicillin
pathway genes with different promoters known to vary in
strength and expression dynamics (Fig. 2, Supplementary Fig. 2).
We used this approach to first optimize the production of the
ACV Nrp intermediate (Supplementary Fig. 2), and then the
conversion of ACV to benzylpenicillin (Fig. 2).
For the optimization of ACV production, we cloned the two
genes for ACV biosynthesis with different pairs of promoters on a
low-copy centromeric plasmid and measured ACV yields from
transformed BY4741 yeast by LCMS. All strains constructed
outperformed our Sc.A1 strain (B20 ngml 1) and one combi-
nation, pcbAB with pTDH3 promoter and npgA with pPGK1
promoter, generated a strain (Sc.A2) that even outperformed
yeast with the high-copy number pESC-npgA-pcbAB 2-micron
plasmid containing strong galactose-inducible promoters
(B280 versus B70ngml 1; Supplementary Fig. 2, Supplementary
Table 1).
To optimize conversion of ACV to benzylpenicillin, we next
exploited one-pot combinatorial DNA assembly using Golden
Gate cloning to make a diverse library of high copy plasmids in
which genes pcbC, pclA and penDE are each expressed from one
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of ten randomly assigned promoters that span a range of
strengths (Fig. 2a). Eight different constitutive promoters and two
galactose-inducible promoters were included. The constitutive
promoters were classified as ‘strong’ (4 total), ‘medium’ (2 total)
or ‘weak’ (2 total) promoters according to their characterization
in a previous study (Supplementary Table 7)17. The resultant
plasmid library, with a theoretical diversity of 1,000 members,
was transformed into the Sc.A2 strain and a total of 160 colonies
were individually screened by LCMS for benzylpenicillin
production in Synthetic Complete medium minus the
appropriate amino acids for selection, and with glucose as the
carbon source (Supplementary Table 2).
From the screened colonies, the plasmids from the top 10 out
of 20 strains showing detectable production of benzylpenicillin by
LCMS (Supplementary Table 2) were sequenced to determine the
promoter combinations for pcbC, pclA and penDE that direct
efficient biosynthesis in S. cerevisiae. Sequencing revealed an
apparent over-representation of strong constitutive promoters at
the pclA gene (10 out of 10) and of medium constitutive
promoters at the pcbC gene (5 out of 10) in strains with
benzylpenicillin production (Fig. 2b, Supplementary Table 3).
These results suggested that either a strong level of pclA
expression is required for optimal benzylpenicillin production
in S. cerevisiae, or that our combinatorial DNA assembly had an
unintended bias for incorporation of these promoter parts into
the final plasmid library. To rule out any bias in our library
assembly, we used a MinION DNA sequencer (Oxford Nanopore
Technologies) to provide long-read sequencing of the
assembly products pooled from all stages in our plasmid library
construction (Fig. 2a). The ability of nanopore sequencing to
routinely return read lengths above 5 kb make it well suited
to determining the full-length products of modular DNA
construction19. Two-directional (2D) reads of products
from multigene assembly revealed in vitro construction of over
one hundred plasmids containing different combinations of
promoters in front the three pathway genes. No significant bias
for incorporation was seen during either of the DNA assembly
steps compared to the distribution expected by chance (Fig. 2c,
Supplementary Table 3, w2 test), whereas a clear bias was seen for
strong promoters associated with pclA in all yeast strains able
to perform detectable benzylpenicillin biosynthesis (Fig. 2c,
Supplementary Table 3, Fisher’s exact test).
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Figure 1 | Production of benzylpenicillin by engineered S. cerevisiae. (a) Benzylpenicillin biosynthesis requires a five-enzyme pathway where
alpha-aminoadipic acid, cysteine and valine are first converted to the tripeptide ACV by pcbAB and npgA. ACV is then converted to benzylpenicillin by pcbC,
pclA and penDE. (b) Strain Sc.A1 (S. cerevisiae BY4741 with genomically integrated pcbAB and npgA genes) produces ACV as observed by LCMS analysis.
Parallel diagonal lines in the cartoon for the pcbAB gene represent that this very large gene is not drawn to scale with npgA. To produce benzylpenicillin,
strain Sc.A1 was transformed with a plasmid expressing pcbC, pclA and penDE to make strain Sc.P1. (c) LCMS counts versus retention time is shown for the
detection of ACV (left) and benzylpenicillin (right), for an ACV standard (light blue) and a benzylpenicillin standard (light green) as well as for supernatant
from a wild-type culture (brown), an Sc.A1 culture (blue), an Sc.P1 culture (green) and a culture of strain without peroxisomal targeting of pclA and penDE
(Sc.P1x, dark green). All cultures were grown at 20 C in the presence of 5mM AAA and 0.25mM phenylacetic acid (required for the last step of
benzylpenicillin biosynthesis). Dashed diagonal lines indicate the bounds of the x axis and the centres of the relevant peaks. Rounded LCMS counts of the
tallest peak for both ACV and benzylpenicillin detection are indicated on the y axis, and areas under each peak are given in parentheses in the legend. Mass
spectra are included as Supplementary Data 2. (d) Benzylpenicillin is secreted as shown by concentration-normalized log10 values of LCMS counts for cell
pellets and media for both ACV and benzylpenicillin from Sc.P1 cultures grown as in c. Error bars show s.d. for three biological replicates.
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Antibiotic action of the spent yeast culture media. Optimiza-
tion of the biosynthesis pathway through combinatorial cloning
with alternative promoters led to aB30-fold increase in yields of
secreted benzylpenicillin compared to our first strain Sc.P1
(B90 pgml 1). The highest producer, strain Sc.P2, secretes
benzylpenicillin into its growth media at a concentration calcu-
lated to be around 3 ngml 1 (Fig. 2b). Using this strain, we next
sought to test whether benzylpenicillin secreted by engineered S.
cerevisiae shows expected bioactivity. The secreted levels of
benzylpenicillin are similar to those required for antibiotic action
against various bacteria such as Streptococcus pyogenes20.
Therefore, to test the bioactivity of the secreted benzylpenicillin,
we diluted liquid cultures of S. pyogenes with spent culture
medium from either Sc.P2 or from an inactivated version of Sc.P2
(Sc.P2x) that has a premature termination codon in pcbAB and
does not produce benzylpenicillin (Fig. 3a). Overnight growth of
S. pyogenes was almost completely inhibited in the presence of
spent culture media from Sc.P2. By contrast, spent culture media
from the inactivated Sc.P2x strain resulted in normal growth of S.
pyogenes (Fig. 3b). Simultaneous exposure of S. pyogenes to a
range of concentrations of benzylpenicillin standards revealed
that the spent culture media from Sc.P2 had the antibiotic action
equivalent to 3 ngml 1 of benzylpenicillin being present. This
concentration was then verified in parallel by LCMS analysis of
the Sc.P2 culture media, demonstrating that the benzylpenicillin
secreted by S. cerevisiae has the same bioactivity as the
commercially obtained standard.
To demonstrate the utility of this simple bioactivity assay,
we next employed it to further explore pathway expression
optimization by exchange of pcbC, pclA and penDE promoters.
The finding from the previous screen (Fig. 2) that stronger
promoters seemed to be favoured at the pclA and penDE
genes for high benzylpenicillin yields led us to test a new
promoter library especially enriched for stronger promoters
(Supplementary Table 10). Specifically, we constructed a
combinatorial library of strains harbouring the pcbAB-npgA
plasmid from Sc.A1 as well as different variants of a second
plasmid bearing the pcbC, pclA and penDE genes, each driven by
one of six different promoters ranging from medium to strong.
We screened 120 different strains over two 96-well plates and
selected 12 strains that exhibited a range of S. pyogenes inhibition
(Fig. 3c). To verify the bioactivity screen, we validated
benzylpenicillin yields of these strains by LCMS (Fig. 3d)
revealing a clear relationship between the concentration of the
secreted antibiotic and the inhibition of bacterial growth. From
this new screen, five strains gave higher benzylpenicillin yields
than Sc.P2 when measured by LCMS, with two giving yields of
45 ngml 1, a more than a 50-fold increase in yield relative to
our original producer strain, Sc.P1 (B90 pgml 1). Sequence
analysis of the three strains secreting the highest yields (Fig. 3e)
revealed no clear pattern of use among the strong promoters
whose expression strengths cover an order of magnitude
(Supplementary Table 12). The exact relationship between
benzylpenicillin production and the promoter strengths of the
pcbC, pclA and penDE genes is likely to be more complex and
could be further explored in the future by metabolic flux analysis
approaches21. Encouragingly, the results from our screen
illustrate how a simple assay based on antibiotic activity can be
used to quickly and cheaply screen hundreds of strains for
productivity without the need for LCMS.
DNA assembly
MinION
DNA sequencing
pe
n 
G
 (n
g m
l–1
)
pcbC pclA penDE
pcbC
pclA
pclA
penDE
Single
Multiple
Producers
Single
Multiple
Producers
Sanger readspcbAB
pTDH3 pPGK1
npgA
In vivo producers
Single
Multiple
Producers
100%0%
penDE
a b
c
pcbC
3.5
3
2
1
0
0.5
1.5
2.5
Strong
Weak
Medium
Inducible
Figure 2 | Optimization of benzylpenicillin production in S. cerevisiae. (a) Construction and sequencing of a library with alternative promoters for pcbC,
pclA and penDE. Ten different promoters of four categories (strong, medium, weak or inducible) were randomly used to drive expression of each of the
genes responsible for conversion of ACV to benzylpenicillin. Plasmid libraries of single genes with different promoters were initially constructed and then
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promoters. (b) Concentrations of benzylpenicillin secreted into the supernatant by the ten yeast strains selected from the promoter screen. The best
producing strain makes B3 ngml 1 of benzylpenicillin as determined by LCMS. Under each bar, the category of the promoter in front of each gene is
shown. Error bars represent s.e.m. from three biological replicates. (c) Comparison of the percentage of promoters from each of the four categories for each
pathway gene during Golden Gate library construction (single and multiple gene steps) and among the ten benzylpenicillin producing yeast strains as
determined by DNA sequencing.
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Discussion
Our results demonstrate, to the best of our knowledge, the
first biosynthesis of a bioactive Nrp antibiotic from engineered
S. cerevisiae yeast. After achieving production of benzylpenicillin,
we improved yields by optimizing pathway enzyme expression
and exploited long-read nanopore sequencing to verify the
combinatorial DNA assembly of our libraries to ascertain the best
combination of promoter strengths for increased yields. We
observed that this required strong expression of the peroxisomally
located enzyme pclA. As engineered heterologous biosynthesis of
penicillin has only previously been observed with Hansenula
polymorpha, a methylotrophic yeast with large peroxisomes22,
this suggests that boosting peroxisomal expression further, for
example by increasing peroxisome formation, by may be a future
approach to improve yields from our S. cerevisiae, which
are currently three orders of magnitude below P. chrysogenum
yields and two orders of magnitude below yields achieved in
H. polymorpha22. Alternatively, further yield improvements could
also be achieved by using other metabolic engineering
strategies23,24. However, as existing production strategies
already achieve sufficient yields of penicillin for global medical
needs, increasing the productivity of our engineered S. cerevisiae
strains is not a priority.
Instead, we view our achievement in S. cerevisiae as a paradigm
for establishing complex fungal biosynthesis pathways in a
standard chassis organism used extensively in research and
industry. Given the impressive wealth of genetic tools and the
ease of engineering with this microbe, we see it as the ideal
testbed for screening and diversifying fungal pathway biosynth-
esis. Thus, the real utility of our work is to lay the foundations for
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future engineering projects that can mix and match heterologous
NRPS enzymes with tailoring enzymes. We especially anticipate
that expression and genetic manipulation of other bioactive
Nrp pathways in S. cerevisiae could advance the screening of
engineered or newly discovered NRPS enzymes from fungi. NRPS
enzymes represent a particularly attractive class of enzymes for
engineering efforts as they are inherently modular with each
module region recognizing one amino acid and incorporating
it into the Nrp product15,24. NRPS modules incorporate both
the standard 20 amino acids, as well as hundreds of
non-proteinogenic amino acids, including D-enantiomers25.
Thus by combining different modules together it should be
possible make chimeric NRPS enzymes that produce thousands of
novel Nrp molecules predisposed by evolution for bioactivity26.
However, determining the structural boundaries of modules
within natural NRPS enzymes has so far proved extremely
challenging due to the difficulty in obtaining structures for these
massive enzymes27,28. An alternative approach to structure-
guided mutagenesis is exhaustive mutation and screening. Simple
biological screens such as those based on the antibiotic activity
shown in this study could help pave the way towards true
combinatorial biosynthesis of novel bioactive Nrp molecules.
Such endeavors are extremely important in light of widespread
resistance to antibiotics and the decreasing number of new
antibiotics developed through traditional means29.
Methods
Construction of strains. Strain Sc.A1 was made by replacing the TRP1 gene in
BY4741 with the pcbAB-npgA segment from the pESC-npgA-pcbAB plasmid from a
previous study12. A URA3 gene from K. lactis was integrated upstream of the
pcbAB gene to allow genomic integration and the use of media without uracil was
used to enable comparison of the ACV production of this strain with that of a
BY4741 strain transformed with the ura-marked pESC-npgA-pcbAB plasmid.
A full genetic map of the altered TRP1 locus is provided as an annotated Genbank
file in Supplementary Data 1. The PEX5 deletion strain was constructed by
CRISPR-enhanced recombination. Linear fragments encoding Cas9, a gRNA
retargeted to PEX5 and an overlap extension PCR product encoding a whole-CDS
deletion of PEX5 were co-transformed into BY4741 following the protocol outlined
at benchling.com/pub/ellis-crispr-tools. Oligonucleotides used retarget the gRNA
and generate the deletion template PCR product are listed in the Supplementary
Information. To change the native P. chrysogenum Peroxisome Targeting
Sequences (PTS1) to those of S. cerevisiae for the pclA and penDE genes, the native
C-terminal tripeptide SKI for pclA and ARL for penDE were both changed to the
S. cerevisiae PTS1 tripeptide SKL.
All other strains used in all experiments were constructed by transforming
plasmids into BY4741 or into the Dpex5 strain. These are specified in
Supplementary Table 4. Annotated Genbank files of all plasmids are provided in
Supplementary Data 1.
Growth of strains for ACV and penicillin production. For all ACV and penicillin
producing experiments, cultures were prepared in the following manner. After
initial construction, strains were stored in 25% glycerol stocks at  80 C. For
recovery of strains from glycerol stocks, strains were streaked onto the appropriate
selective media agar plates and incubated at 30 C for 2–3 days. Single colonies
were picked using a pipette tip and used to innoculate 4ml overnight cultures in
synthetic complete media minus the appropriate amino acids for selective pressure
with either glucose or galactose as the carbon source. There were no secondary
precultures. For plate based assays, cells were grown overnight at 700 r.p.m. at
30 C. For 50ml falcon tube based assays, cells were grown at 225 r.p.m. at 30 C.
Overnight cultures were then back-diluted into production media and grown at
20 C (216 r.p.m.) for 20 h (for plate based assays) or until the OD600 reached
between 0.6 and 0.8 (for 50ml falcon tube assays). Supplementary Table 5 details
the composition of production media for different experiments.
Fluorescence microscopy. Microscopy for Supplementary Fig. 1 was carried out
with a Nikon Eclipse Ti, using the NIS Elements AR software. The objective was set
at  60. Slides were fixed with yeast cells to visualize. The excitation wavelengths
for detection of Venus, mRuby2 and mTurquoise2 fluorescence were 535, 590 and
535 nM, respectively.
Preparation of standards and samples for LCMS. For all LCMS experiments,
standards were prepared as follows. ACV standards were prepared by dissolving
ACV (BACHEM H-4204) in water to a concentration of 10 ng ml 1 and
making three 10-fold dilutions. This gave four standards with concentrations of
10 ng ml 1, 1 ng ml 1; 100 pg ml 1; 10 pg ml 1. Benzylpenicillin standards were
prepared by dissolving the sodium salt of penicillin G (Sigma P3032) in water.
The same concentrations were used for benzylpenicillin as were used for ACV.
Cellular extracts for LCMS for the data in Fig. 1 were prepared as follows: 30ml
of cell culture was collected at an OD600 of 0.6. Cell culture was centrifuged at
7,000g for 10min, and supernatant was either kept for LCMS (as in Fig. 1d) or
discarded. The cell pellet was resuspended in 100ml methanol. A volume of 50 ml of
the resuspension was transferred to a microcentrifuge tube with 25 ml of glass beads
(Sigma G8772-100G) on ice. The tube was then vortexed for 30 s and then placed
on ice for 30 s, and these two steps were repeated three times (for a total of four sets
of vortexing and incubation on ice). The tube was then centrifuged at 12,000g for
30min, and 40 ml of supernatant was aliquoted to a separate tube for LCMS
measurement. Supernatants for LCMS from cultures grown in 96 well plates in
Fig. 2 were obtained by centrifuging plates at 3,000g for 30min.
Liquid chromatography mass spectrometry. An LC/MS/MS method was
developed for the measurement of ACV and benzylpenicillin, using an Agilent
1290 LC and 6550 quadrupole time-of-flight (Q-ToF) mass spectrometer with
electrospray ionization (Santa Clara, CA). The LC column used was an Agilent
Zorbax Extend C-18, 2.1 50mm and 1.8 mm particle size. The LC buffers were
0.1% formic acid in water and 0.1% formic acid in acetonitrile (v/v).
The gradient elution method is detailed in Supplementary Table 6.
Quantification was based on the LC retention times of standards and the area of
accurately measured diagnostic fragment ion for each molecule (Supplementary
Table 6). The protonated molecules of each analyte [MþH]þ , were targeted and
subjected to collision induced dissociation (collision energy 16 eV), with product
ions accumulated throughout the analysis. Solutions of benzylpenicillin and ACV
standards in water were used to generate calibration curves.
The linear range of the method was determined by injecting standards over a
range of concentrations. The lower limit of detection was determined by the
amount a sample resulting in a peak with a signal-to-noise of 3:1. The lower limit
of quantification was taken to be the concentration of analyte that produced a
signal-to-noise of 10:1. The lower limit of detection and lower limit of
quantification for benzylpenicillin were found to be on-column injections of 5 and
20 pg, respectively. Further specifications are found in Supplementary Table 6.
All mass spectra are included as Supplementary Data 2.
Calculation of ACV and benzylpenicillin yield from LCMS data. For
both ACV and benzylpenicillin, pure chemical standards were run at the following
concentrations: 10 ngml 1, 100 ngml 1, 10mgml 1, 100 mgml 1. The
corresponding LCMS counts for these standards were plotted against the
concentrations of the standards and the linear range of the resulting plot was
used to construct a line of best fit in excel. The corresponding line equation was
used to obtain values for the yield in ngml 1 of ACV and benzylpenicillin from
experimental samples based on the LCMS counts for these molecules.
Promoter screens for optimizing ACV to penicillin conversion. The assembly of
multigene (pcbC, pclA, penDE) plasmids with ten randomized promoters
(Supplementary Table 7) was split into two stages: assembly of single-gene
constructs, then assembly of multigene constructs. For single-gene construct
assembly, an equimolar mix of all ten promoters was made with a final
concentration of 50 fM (referred to as ‘promoter mix’, Supplementary Table 9).
This was used as a type 2 plasmid according to the yeast toolkit specification17.
Then, Golden Gate reactions were set up with the following parts according to the
Yeast Toolkit cassette plasmid golden gate assembly protocol (Supplementary
Table 9).
Each of the three reactions were transformed into E. coli, and for each of the
three transformation plates, transformant colonies were mixed together into a
single overnight culture each. From each of the three resulting cultures a plasmid
library was prepared, of which an aliquot was used to construct a pooled sample for
nanopore sequencing (see nanopore sequencing section). The three resulting
single-gene plasmid libraries were used to set up a single multigene golden gate
reaction according to the yeast toolkit protocol (Supplementary Table 9).
This Golden Gate reaction was transformed into E. coli, and all transformant
colonies were mixed together into a single overnight culture. A multigene plasmid
library was prepared from this overnight culture. Part of this plasmid library was
prepared for nanopore sequencing (see nanopore sequencing section), while 4 mg
was used to transform into S. cerevisiae strain Sc.A2. The resulting transformants
were screened by LCMS for the production of benzylpenicillin (Supplementary
Table 2) and the promoter regions of the multigene plasmids from producer strains
were identified by Sanger sequencing.
A second promoter screen was carried out to test the suitability of the
S. pyogenes growth inhibition assay for identifying strains with improved
benzylpenicillin yield. Strains were constructed in analogous fashion to that
described above, but with different promoters (Supplementary Tables 10 and 11).
Nanopore sequencing of library construction. To enrich for the penicillin
pathway assembly DNA and remove assembly vector backbone DNA, the
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multigene assembly library was digested with EcoRI and AlwNI. Restriction
digest products ranging from 5,616 to 6,117 bp were isolated by agarose gel
electrophoresis and purified using a QIAquick gel extraction kit (Qiagen). The
single pathway gene assembly libraries were similarly enriched by digestion with
BsmBI and AlwnI. Restriction digest products ranging from 2,062 to 2,229, 2,549 to
2,716 and 1,885 to 2,052 bp for the pcbC, pclA and penDE assemblies, respectively,
were purified.
Enriched assembly DNA for the multigene and single gene assemblies was
quantified on a Qubit 2.0 fluorometer (Thermo Fisher Scientific) using a Qubit
dsDNA HS Assay Kit (Thermo Fisher Scientific). The four samples were combined
to a give an equimolar mix (assuming a molecular weight for each assembly based
on the mean promoter length) with a total DNA content of 2.6 mg in 45 ml dH2O.
DNA underwent end repair using NEBNext FFPE DNA Repair Mix (M6630,
New England Biolabs) according to the manufacturer’s instructions. The repaired
DNA was recovered using Agincourt AMPure XP beads (A63880, Beckman
Coulter), washed twice in 200 ml 70% ethanol and eluted in 46ml dH2O. DNA was
then dA-tailed using NEBNext Ultra II End Repair/dA-Tailing Module (E7546,
New England Biolabs) according to the manufacturer’s instructions and recovered
using Agincourt AMPure XP beads as before, eluting in 30 ml dH2O.
The dA-tailed library DNA was then processed using Blunt/TA Ligase
Master Mix (M0367, New England Biolabs) and a Nanopore Sequencing Kit
(SQK-NSK007, Oxford Nanopore Technologies) according the manufacturer’s
instructions to ligate adaptors and tethers to the library. 50 ml Dynabeads MyOne
Streptavidin C1 beads were washed twice in buffer BBB (Nanopore Sequencing Kit)
and then resuspended in 100 ml BBB. These beads were then added to the processed
DNA sample and mixed for 5min at room temperature. Beads were washed twice
with 150ml BBB before eluting the sample in 25 ml ELB (Nanopore Sequencing Kit).
The library was quantified by Qubit as before and yielded a total of 253 ng.
Nanopore sequencing. A fresh MinION R7 Flow Cell Mk I (FLO-MIN104,
Oxford Nanopore Technologies) was loaded into a MinION MK I (MIN-MAP002,
Oxford Nanopore Technologies) and primed using a Nanopore Sequencing Kit
according to the manufacturer’s instructions. The sequencing mix was generated by
combining 75ml RNB, 65ml NFW and 4 ml Fuel Mix (Nanopore sequencing kit)
before adding 6 ml of the processed DNA library. This sequencing mix was loaded
into the flow cell and sequenced using the 48 h sequencing script on MinKNOW
(Oxford Nanopore Technologies). After 18 h, the script was stopped and a fresh
sequencing mix was prepared and loaded into the flow cell. The 48 h sequencing
script was then restarted. This reloading process was repeated after a further 4.5 h.
The sequencing script was stopped once read acquisition had slowed to less than 1
successful read in a 5min period.
Analysis of nanopore sequencing data. Oxford Nanopore’s cloud-based
Metrichor application ‘2D Basecalling for SQK-MAP006 v1.69’ was used to
basecall data from a MinION run that used R7.3 chemistry. Poretools30
(https://github.com/arq5x/poretools) was used to extract sequence files and the
program lastal v658 (http://last.cbrc.jp/) was used to align the 2D reads to a
database of all the potential promoters and all combined CDSþ terminators using
options -s2 -T0 -Q0 -a1 -fTAB -e50*. To remove reads corresponding to other
DNA sequences present, the database was also populated with sequences for
AmpRTerm_AmpR_AmpRProm (part of the single assembly plasmid backbone),
His3Prom_His3Term_2Micron_KanRTerm_KanR_KanRProm (part of the
multiple assembly plasmid backbone), ColE1 (part of both the single and multiple
assembly plasmid backbone), and the lambda phage whole genome.
To build up a picture of which part of a plasmid each read represented, a
custom-built script ordered alignments first by read, then by read coordinates. It
then identified reads as originating from a particular plasmid by looking at plasmid
regions in the database that each read had aligned to. These identified reads were
required to be a similar length (within 15%) to the sum of lengths of regions of
plasmids that they were aligned to. The script identified digested multiple gene
assemblies, digested single gene assemblies and, due to reduced function of BsmBI,
non-digested single assemblies. To be identified as a digested single gene assembly,
the read was also required to start and finish within 50 bp of the start and end of
the first and final regions respectively. This minimized the chance of misidentifying
a multigene assembly as a single-gene assembly. The promoters at each position
within these identified reads were recorded.
*[-s2 use both query strands. -T0 local alignment. -Q0 use fasta as input. -a1 gap
existence cost of 1. -fTAB tabular output -e50 minimum gap alignment score of
50.]
S. pyogenes growth inhibition assays. An overnight culture of S. pyogenes (H584,
M1 type) was grown for 24 h at 37 C (5% CO2) in Todd Hewitt Broth. This culture
was diluted in 10 Todd Hewitt Broth to an optical density of OD600 0.2. In
separate wells of an optically transparent 96-well plate (VWR 3596) 10 ml of this
solution was added to 90ml of either a known concentration of benzylpenicillin
dissolved in 0.25mM phenylacetic acid or 90 ml of spent culture media from
Sc.P2 or Sc.P2x or other potential benzylpenicillin-producing strains grown in
production conditions. Sc.P2x is a variant of Sc.P2 known to not produce
benzylpenicillin due an inactive pcbAB caused by mutation in the coding region of
the gene’s terminal module region. OD600 values from the bacterial cultures were
then measured again after overnight growth at 37 C. The percentage growth
inhibition caused by spent culture media for each strain was calculated by dividing
the fold-change in OD600 overnight caused by that spent culture media by the
overnight OD600 fold-change caused by the control media (from Sc.P2x cells) and
subtracting this from 100%.
Code availability. Custom code for assigning nanopore sequencing reads to
promoters in the first promoter screen (Fig. 2) is provided as part of Supplementary
Data 3.
Data availability. Plasmid construct sequences are provided in Supplementary
Data 1, LCMS spectra are available in Supplementary Data 2 and nanopore
sequencing files are provided as Supplementary Data 3.
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